Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Mirkin Wins First NIH Director's Pioneer Award

Chad A. Mirkin, Ph.D., has been selected as one of the first recipients of the National Institutes of Health (NIH) Director's Pioneer Award.

Nanosphere Inc. Founder, Chad A. Mirkin, Ph.D., Wins First NIH Director's Pioneer Award

Northbrook, Ill., October 5, 2004

Nanosphere Inc., a nanotechnology-based life sciences company, today announced its founder, Chad A. Mirkin, Ph.D., has been selected as one of the first recipients of the National Institutes of Health (NIH) Director's Pioneer Award. The $2.5 million that Dr. Mirkin will receive is designed to support highly innovative ideas and approaches to critically important scientific questions. Dr. Mirkin is one of only nine researchers chosen from a field of 1,350 nominees.

"This award recognizes the significant contributions of Dr. Mirkin's nanotechnology research to the life sciences and their potential to improve medical care," said William Moffitt, Nanosphere's Chief Executive Officer.

Dr. Mirkin will use this new award to test far-ranging ideas with the potential to make extraordinary contributions to medical research including further exploration of breakthrough applications for his ultra-sensitive protein detection technology first reported in the September 2003 issue of Science.

The ability to study biological behavior at the cellular level with nanotechnology tools is unprecedented. Ultra-sensitive protein detection will enable the discovery and validation of new biomarkers with up to one million times more sensitivity than current methods. This level of sensitivity can lead to broader and earlier diagnosis of illnesses from cancer to Alzheimer's disease.

This method for biomarker detection at extremely low concentrations has been exclusively licensed to Nanosphere. Moreover, new inventions arising from Dr. Mirkin's work in the field of nanoparticles are licensed exclusively to Nanosphere for commercialization in the field of diagnostics and life sciences.

Nanosphere, a privately held company with headquarters in Northbrook, Illinois, is developing and commercializing nanotechnology platforms that set new standards in patient care and public safety. Nanosphere's technology enables the discovery of new biomarkers at concentrations previously undetectable through traditional means while addressing the persistent need for simplified molecular testing for DNA, RNA and proteins.

Wendy Emanuel
Nanosphere Inc.

Copyright © Nanosphere

If you have a comment, please us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links


National Institutes of Health

Related News Press


Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011

Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011

Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010

Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010


Basque researchers turn light upside down February 23rd, 2018

Stiffness matters February 23rd, 2018

Histology in 3-D: New staining method enables Nano-CT imaging of tissue samples February 22nd, 2018

Developing reliable quantum computers February 22nd, 2018

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project